CellFE Biotech to Attend BIO Digital ‘21
CellFE Biotech, a gene therapy company focused on developing a microfluidics-based platform for cell engineering, will be attending the Bio Digital conference next week from June 14-18, 2021. While the conference will feature live and on-demand sessions, as well as presentations in the Innovation Stage, industry participants are able to use the events One-on-One Partnering feature for business development networking. The One-on-One digital format will allow participants to meet with industry executives to enhance networking engagement and education about innovative technologies.
During the conference, CellFE will host numerous virtual meetings with pharmaceutical and biotech companies to explore opportunities to implement their revolutionary microfluidic platform. CellFE’s current technology uses microfluidics to genetically engineer cells in a universally adaptable way, allowing for low-cost, high-yield, and highly scalable manufacturing of gene therapies.
Alla Zamarayeva, PhD., co-founder and CEO of CellFE, stated, “CellFE’s ultimate goal is to create a future where gene therapies are the standard, rather than the exception, in healthcare. Despite the pandemic, 2020, was a breakout year for CellFE. We expanded our operations to a larger facility, launched our Alpha instrument, and signed a number of key commercial collaborations. One of our commercial goals is to expand our early access program with key commercial partnerships interested in using our platform. For us, BIO Digital represents an invaluable opportunity to meet with biotech and pharmaceutical industry leaders looking to accelerate their gene therapy programs and solve the most challenging issues.
Register for the event here.Schedule with CellFE for One-on-One Partnering here. Alternatively, please reach out to Craig Darling (Craig@cellFEbiotech.com) to schedule a meeting.
About CellFE
CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally to enable low-cost, high-yield manufacturing of gene therapies at scale.
CellFE’s executive team is composed of members who bring strong expertise in the theoretical and practical aspects of the technology, as well as experience in leadership and business operations. CellFE’s research and development efforts are led by world-class scientists who are passionate about using microfluidics to transform how gene therapies are manufactured.